Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer

Journal of Pathology

Volumn 233, Issue 4, 2014, Pages 425-435

  Kim, Tae Min ^a   Jung, Seung Hyun ^a   Baek, In Pyo ^a   Lee, Sung Hak ^a   Choi, Youn Jin ^a   Lee, Ji Youl ^a   Chung, Yeun Jun ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

cancer genome; copy number; heterogeneity; mutation; prostate cancer

Indexed keywords

BIOLOGICAL MARKER;

AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; ERG GENE; EXOME; GENE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUSION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SCREENING; HUMAN; HUMAN TISSUE; ICOSANOID METABOLISM; MALE; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; PHYLOGENY; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC MUTATION; TMPRSS2 GENE; TUMOR BIOPSY; TUMOR RECURRENCE;

CANCER GENOME; COPY NUMBER; HETEROGENEITY; MUTATION; PROSTATE CANCER;

AGED; BIAS (EPIDEMIOLOGY); BIOPSY; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC HETEROGENEITY; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS;

EID: 84904167564     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4380     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Baca SC, Garraway LA,. The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) 2012; 3: 69.
3. Tomlins SA, Rhodes DR, Perner S, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
4. Barbieri CE, Baca SC, Lawrence MS, et al., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-689.
5. Berger MF, Lawrence MS, Demichelis F, et al., The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
6. Taylor BS, Schultz N, Hieronymus H, et al., Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
7. Wainscoat JS, Fey MF,: Assessment of clonality in human tumors: a review. Cancer Res 1990; 50: 1355-1360.
8. Burrell RA, McGranahan N, Bartek J, et al., The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345.
9. Yates LR, Campbell PJ,. Evolution of the cancer genome. Nat Rev Genet 2012; 13: 795-806.
10. Welch JS, Ley TJ, Link DC, et al., The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
11. Yachida S, Jones S, Bozic I, et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
12. Gillies RJ, Verduzco D, Gatenby RA,. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012; 12: 487-493.
13. Ruiz C, Lenkiewicz E, Evers L, et al., Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci USA 2011; 108: 12054-12059.
14. Andreoiu M, Cheng L,. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41: 781-793.
15. Jenkins RB, Qian J, Lieber MM, et al., Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57: 524-531.
16. Mirchandani D, Zheng J, Miller GJ, et al., Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147: 92-101.
17. Barry M, Perner S, Demichelis F, et al., TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007; 70: 630-633.
18. Mehra R, Han B, Tomlins SA, et al., Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-7995.
19. Lindberg J, Klevebring D, Liu W, et al., Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 2013; 63: 347-353.
20. Brimo F, Sircar K, Chevalier S, et al., Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Cell Tissue Bank 2012; 13: 631-638.
21. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
22. DePristo MA, Banks E, Poplin R, et al., A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
23. Li H, Handsaker B, Wysoker A, et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
24. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
25. Wang K, Li M, Hakonarson H,. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
26. Bengtsson H, Wirapati P, Speed TP,. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009; 25: 2149-2156.
27. Hupe P, Stransky N, Thiery JP, et al., Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004; 20: 3413-3422.
28. Subramanian A, Kuehn H, Gould J, et al., GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007; 23: 3251-3253.
29. Singh D, Febbo PG, Ross K, et al., Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203-209.
30. True L, Coleman I, Hawley S, et al., A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103: 10991-10996.
31. Glinsky GV, Glinskii AB, Stephenson AJ, et al., Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113: 913-923.
32. Lapointe J, Li C, Higgins JP, et al., Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
33. Gerlinger M, Horswell S, Larkin J, et al., Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-233.
34. Felsenstein J., PHYLIP-Phylogeny Inference Package (v 3.2). Cladistics 1989; 5: 164-166.
35. Letouze E, Allory Y, Bollet MA, et al., Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol 2010; 11: R76.
36. Schwarz RF, Trinh A, Sipos B, et al., Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput Biol 2014; 10: e1003535.
37. Saini S, Liu J, Yamamura S, et al., Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas. Cancer Res 2009; 69: 6815-6822.
38. Tomlins SA, Mehra R, Rhodes DR, et al., TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396-3400.
39. Futreal PA, Coin L, Marshall M, et al., A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
40. Lodygin D, Epanchintsev A, Menssen A, et al., Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 4218-4227.
41. Yap TA, Gerlinger M, Futreal PA, et al., Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps10.
42. Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
43. Nik-Zainal S, Alexandrov LB, Wedge DC, et al., Mutational processes molding the genomes of 21 breast cancers. Cell 2012a; 149: 979-993.
44. Nik-Zainal S, Van LP, Wedge DC, et al., The life history of 21 breast cancers. Cell 2012b; 149: 994-1007.
45. Anderson K, Lutz C, van Delft FW, et al., Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
46. Makishima H, Yoshida K, Nguyen N, et al., Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45: 942-946.
47. Nie D, Tang K, Szekeres K, et al., Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann NY Acad Sci 2000; 905: 165-176.
48. Nie D, Che M, Grignon D, et al., Role of eicosanoids in prostate cancer progression. Cancer Metast Rev 2001; 20: 195-206.
49. Sottoriva A, Spiteri I, Piccirillo SG, et al., Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110: 4009-4014.